**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 54792

**Manuscript Type:** CASE REPORT

**Diffuse alveolar hemorrhage with histopathologic manifestations of pulmonary capillaritis: A report of three case****s**

Xie J *et al.* Diffuse alveolar hemorrhage with pulmonary capillaritis

Jun Xie, Ying-Yue Zhao, Jing Liu, Guang-Min Nong

**Jun Xie, Ying-Yue Zhao, Jing Liu, Guang-Min Nong,** Department of Pediatrics, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China

**Author contributions:** Xie J, Zhao Yy, and Nong Gm conceptualized and designed the study; Xie J and Zhao Yy drafted the initial manuscript; Liu J designed the data collection instruments, collected the data, and carried out the initial analyses; Xie J, Zhao Yy, and Liu J reviewed and revised the manuscript; Nong Gm coordinated and supervised the data collection, and critically reviewed the manuscript for important intellectual content; All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

**Corresponding author: Guang-Min Nong, MD, Professor,** Department of Pediatrics,the First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. ngm8525@163.com

**Received:** February 26, 2020

**Revised:** April 28, 2020

**Accepted:** May 21, 2020

**Published online:**

**Abstract**

BACKGROUND

Diffuse alveolar hemorrhage (DAH) is a multicause pulmonary capillary hemorrhage or pulmonary vascular small vessel injury (mainly capillaries, including arteries and veins), causing pulmonary microcirculation blood to accumulate in the alveolar space. DAH is classified by the histological absence or presence of pulmonary capillaritis (PC) and is rarely reported in the literature.

CASE SUMMARY

This is a report of three girls aged 6-11 years with DAH and PC. Two patients had decreased hemoglobin and one had increased erythrocyte sedimentation rate. High-resolution computed tomography showed bilateral diffuse pulmonary infiltrate, and diagnosis of PC was confirmed by lung biopsy. Immunofluorescence test in one case showed granular IgG and a small amount of granular IgA deposit on the alveolar walls, and was negative in the other two cases, describing isolated pauci-immune PC. Treatment was with glucocorticoid alone or combination with immunosuppressants, and the symptoms resolved in all patients.

CONCLUSION

PC is classified as isolated and immune-mediated PC associated with systemic disease. It can be controlled in most children with glucocorticoid alone or combined with immunosuppressants.

**Key words:** diffuse alveolar hemorrhage; pulmonary capillaritis; glucocorticoid; immunosuppressant; lung biopsy; case report

Xie J, Zhao YY, Liu J, NongGM. Diffuse alveolar hemorrhage with histopathologic manifestations of pulmonary capillaritis: A report of three cases. *World J Clin Cases* 2020; In press

**Core tip:** This is a report of three children with diffuse alveolar hemorrhage and pulmonary capillaritis who presented with recurrent hemoptysis: one was antinuclear antibody-positive and two were antibody-negative. The condition can be controlled in patients using glucocorticoid alone or combination of immunosuppressant treatment.

**INTRODUCTION**

Diffuse alveolar hemorrhage (DAH) is a rare, and life-threatening disease in children. It is reported that DAH in children is associated with common causes such as oligoimmunity, immune complex deposition, and others (mainly due to medication)[1]. DAH is divided into DAH in the presence or absence of pulmonary capillaritis (PC), and DAH of cardiac origin[2]. PC is characterized by the presence of cough, shortness of breath, dyspnea, with or without hemoptysis[3], and iron deficiency anemia. Histopathology of PC is manifested as neutrophil aggregation or infiltration at the tight junction of alveolar interstitial and alveolar capillaries[4], as well as nuclear debris. Red blood cells and hemosiderin-laden macrophage cells (HLMs) exuded from capillaries are seen in the alveolar spaces and interstitium. In this report, we describe three patients with PC diagnosed by lung biopsy.

**CASE PRESENTATION**

***Case 1***

A girl aged 6 years and 3 mo presented with repeated pale skin and cough for > 2 years. She was allergic to chicken protein and milk and denied medical history and family genetic diseases. Hemoglobin was 109 g/L, erythrocyte sedimentation rate (ESR) was 48 mm/h, and urinalysis, renal function, coagulation function and serum ferritin were normal. Antinuclear antibody (ANA) (IgG) was positive, immunofluorescence revealed granular type (1: 320), and the other tests were negative. Chest high-resolution computed tomography (HRCT) showed patchy density and ground-glass opacity in multiple lobes (Figure 1A). A right upper lung biopsy showed typical DAH and PC (Figure 2A).

***Case 2***

A girl aged 11 years and 6 mo was admitted to hospital with a 3-year history of recurrent of cough and hemoptysis. She previously had episodes of hemoptysis for which she had received multiple treatments, including antibiotics and glucocorticoids. Laboratory examination revealed hemoglobin 75 g/L. Evaluation was normal for ESR, urinalysis, renal function, ANA, and anti-glomerular basement membrane antibody (GBM). Chest HRCT showed diffuse cystic lesions in bilateral lung fields (Figure 1B). There were no malignant cells in the bronchoalveolar lavage smear, and HLMs were visible. A diagnosis of PC was confirmed on right lung biopsy that showed spilled red blood cells and HLM aggregation, and a small amount of lymphocyte and neutrophil infiltration, typical of DAH and PC (Figure 2B).

***Case 3***

A girl aged 11 years and 11 mo presented to our hospital with a history of recurrent pale skin and hemoptysis for > 1 year. The child had no significant past medical problems, and had no exposure to toxic chemicals, fumes, or other irritants. Auxiliary examination showed hemoglobin 79 g/L. She was admitted; evaluation included normal results for platelets; and ESR, urinalysis, renal function, coagulation function, ANA, and antineutrophil cytoplasmic antibodies were within the normal range. Chest HRCT showed diffuse ground-glass opacity in the bilateral lung fields. Histopathology of the lung biopsy was typical of DAH, but the lesions were mainly in the chronic phase (fibrosis, lymphatic, and plasma cell infiltration) (Figure 2C).

**FINAL DIAGNOSIS**

Case 1 was positive for ANA (IgG) and immunofluorescence test revealed granular IgG, and a small amount of granular IgA deposit on the alveolar wall combined with minimal change glomerulonephritis, which suggested systemic lupus erythematosus (SLE). Cases 2 and 3 were diagnosed with isolated pauci-immune PC (IPPC), which was based on histopathological evidence of PC in the absence of clinical and serological evidence of an underlying systemic disorder.

**TREATMENT**

***Case 1***

the patient was given oral prednisone 10 mg/d (1.58 mg/kg/d) with subsequent gradual taper plan over 3 mo.

***Case 2***

the child was treated with intravenous methylprednisolone 54 mg q12 h (4 mg/kg/d) for 5 d, follow by oral prednisone at a dose of up to 30 mg/d (1 mg/kg/d), and this relieved her symptoms of cough, hemoptysis, and shortness of breath.

***Case 3***

the patient was treated with prednisone 30 mg/d (1.2 mg/kg/d) for 4 mo, gradually reduced to 15 mg/d (5 mg every 2 mo) for 9 mo. This resulted in symptom improvement of the pulmonary hemorrhage.

**OUTCOME AND FOLLOW-UP**

***Case 1***

the patient attended regular outpatient review, and symptoms were improved. Hemoglobin was 128-147.8 g/L; ESR WAS 29 mm/h; chest HRCT showed that the lung lesions improved; and percutaneous kidney biopsy was performed and revealed minimal change glomerulonephritis (Figure 3). Oral prednisone was gradually reduced (5 mg every 2-3 mo), and 14 mo later, the prednisolone dose was tapered from 5 mg/d to a maintenance dose of 5 mg every other day. Follow-up has been completed for 2 years with no evidence of recurrence after discontinuation of prednisone.

***Case 2***

Follow-up hemoglobin concentration fluctuated at 117.4-128.8 g/L; ESR was normal; chest HRCT showed partial absorption of inflammatory lesions, and the remaining lesions were similar to before. After oral administration of prednisone for 2 years, the dose was reduced to 5 mg/d. During that period, the patient was hospitalized twice for DAH, and the dose of prednisone was increased to 60 mg/d (1.5 mg/kg/d), and methotrexate was added at 12.5 mg once weekly. Four years after the initial diagnosis, the child remained on therapy and the symptoms had resolved, but she developed Cushing’s syndrome.

***Case 3***

the patient had regular follow-up visits, and she had no cough or hemoptysis, no pale skin. Routine blood examination showed hemoglobin 112.6-140 g/L, and ESR, routine urinalysis and anti-GBM antibody were negative. Chest HRCT showed that the lung lesions were not aggravated compared with before. The patient has been stable and asymptomatic for 3 years.

**DISCUSSION**

PC is a histopathological type of DAH that is characterized by inflammatory cell infiltration and blood accumulation in the alveolar cavity[5,6]. Two of the present cases were diagnosed with IPPC, which was based on histopathological evidence of PC in the absence of clinical and serological evidence of an underlying systemic disorder[3]. In Case 1, ANA autoantibodies (IgG) were positive and immunofluorescence test revealed granular IgG, a small amount of granular IgA deposit on the alveolar wall, combined with minimal change glomerulonephritis, which suggested SLE[7,8]. Only 5% of SLE patients reportedly have DAH, but PC, IgG, and complement C3 immune complex deposits are observed microscopically in nearly 50% of cases[8]. There is no unified diagnostic standard for SLE with PC. The clinical symptoms of most PC patients are inconspicuous, and lung pathology is the gold standard for diagnosis.

Currently, glucocorticoids alone or combined with immunosuppressants to control inflammation and autoimmune response remain the standard treatment for most patients. It is reported that glucocorticoids (starting with intravenous methylprednisolone 2-4 mg/kg/d for 1-3 d, followed by oral prednisone 1-2 mg/kg/d; or starting with oral prednisone 1-2 mg/kg/d)[1] are effective, but fail in some cases. When glucocorticoids are ineffective, immunosuppressants are recommended, including oral methotrexate, hydroxychloroquine, and azathioprine[9-11]. After addition of immunosuppressants, the condition in most cases can be controlled[9,10]. Rituximab and recombinant-activated human factor VIIa seem to be a new promising therapy[3,12].

**CONCLUSION**

PC is classified as isolated PC and immune-mediated PC associated with systemic disease. The condition can be controlled in most children using glucocorticoids alone or in combination with immunosuppressants.

**REFERENCES**

1 **Green RJ**, Ruoss SJ, Kraft SA, Duncan SR, Berry GJ, Raffin TA. Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management. *Chest* 1996; **110**: 1305-1316 [PMID: 8915239 DOI: 10.1378/chest.110.5.1305]

2 **Afessa B**, Tefferi A, Litzow MR, Krowka MJ, Wylam ME, Peters SG. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. *Am J Respir Crit Care Med* 2002; **166**: 641-645 [PMID: 12204858 DOI: 10.1164/rccm.200112-141cc]

3 **Thompson G**, Specks U, Cartin-Ceba R. Isolated pauciimmune pulmonary capillaritis successfully treated with rituximab. *Chest* 2015; **147**: e134-e136 [PMID: 25846537 DOI: 10.1378/chest.14-1884]

4 **Vece TJ**, Fan LL. Diagnosis and management of diffuse lung disease in children. *Paediatr Respir Rev* 2011; **12**: 238-242 [PMID: 22018037 DOI: 10.1016/j.prrv.2011.04.001]

5 **Franks TJ**, Koss MN. Pulmonary capillaritis. *Curr Opin Pulm Med* 2000; **6**: 430-435 [PMID: 10958235 DOI: 10.1097/00063198-200009000-00008]

6 **Lee AS**, Specks U. Pulmonary capillaritis. *Semin Respir Crit Care Med* 2004; **25**: 547-555 [PMID: 16088498 DOI: 10.1055/s-2004-836146]

7 **Hannah JR**, D'Cruz DP. Pulmonary Complications of Systemic Lupus Erythematosus. *Semin Respir Crit Care Med* 2019; **40**: 227-234 [PMID: 31137062 DOI: 10.1055/s-0039-1685537]

8 **Barile-Fabris L**, Hernández-Cabrera MF, Barragan-Garfias JA. Vasculitis in systemic lupus erythematosus. *Curr Rheumatol Rep* 2014; **16**: 440 [PMID: 25023725 DOI: 10.1007/s11926-014-0440-9]

9 **Flanagan F**, Glackin L, Slattery DM. Successful treatment of idiopathic pulmonary capillaritis with intravenous cyclophosphamide. *Pediatr Pulmonol* 2013; **48**: 303-305 [PMID: 22573417 DOI: 10.1002/ppul.22583]

10 **Kupfer O**, Ridall LA, Hoffman LM, Dishop MK, Soep JB, Wagener JS, Fan LL. Pulmonary capillaritis in monozygotic twin boys. *Pediatrics* 2013; **132**: e1445-e1448 [PMID: 24127476 DOI: 10.1542/peds.2013-0154]

11 **Stainer A**, Rice A, Devaraj A, Barnett JL, Donovan J, Kokosi M, Nicholson AG, Cairns T, Wells AU, Renzoni EA. Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults. *BMC Pulm Med* 2019; **19**: 185 [PMID: 31651292 DOI: 10.1186/s12890-019-0947-y]

12 **Park JA**, Kim BJ. Intrapulmonary recombinant factor VIIa for diffuse alveolar hemorrhage in children. *Pediatrics* 2015; **135**: e216-e220 [PMID: 25548333 DOI: 10.1542/peds.2014-1782]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patients for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors have no potential conflicts of interest to disclose.

**CARE Checklist (2016) statement:** The manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** February 26, 2020

**First decision:** April 21, 2020

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): C

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Abe Y **S-Editor:** Gong ZM **L-Editor:** Filipodia **E-Editor:**


**Figure Legends**

C:\Users\June\Desktop\PC材料\Fig 1.tif

**Figure 1 Chest high-resolution computed tomography.** A: Reduced lucency of both lungs, patchy density and ground-glass opacity were seen in multiple lobes with fuzzy boundaries; B: Diffuse cystic lesions in both lungs and patchy opacity with fuzzy boundaries in multiple lobes; C: Diffuse ground-glass opacity was observed in both lungs with fuzzy boundaries.

C:\Users\June\Desktop\Fig2.tif

**Figure 2 Hematoxylin and eosin staining.** A: Aggregation of hemosiderin-laden macrophage cells (HLMs) within the alveolar compartment (long arrow), alveolar interval are mild fibrous thickening and neutrophil infiltrate (short arrow) (400 ×); B: Acute extravasation of fibrin and red blood cells, HLM deposits in the alveolar cavities (long arrow) and neutrophil infiltrates (short arrow) (400 ×); C: Partial lung tissue fibrosis and HLM deposits were observed in the alveolar cavities (long arrow) and neutrophil infiltrates (short arrow) (400 ×).



**Figure 3 Hematoxylin and eosin staining.** Twenty nonsclerotic glomeruli were identified by light microscopy, which mainly presented as mesenteric proliferative changes. No glomeruli contained fibrous crescents and no proliferative changes were observed in the endocapillary or extracapillary areas (400 ×).